Clinical Trials
- Thyroid and Other Endocrine Cancers, Pancreatic Cancer
Randomized Phase II Trial of Postoperative Adjuvant Capecitabine and Temozolomide Versus Observation in High-Risk Pancreatic Neuroendocrine Tumors
- Colorectal Cancer
Randomized Phase II Selection Study of Ramucirumab and Paclitaxel Versus FOLFIRI in Refractory Small Bowel Adenocarcinoma
- Liver Cancer
A Phase II Trial of Durvalumab With Gemcitabine and Cisplatin as Neoadjuvant Therapy for High-Risk Resectable Intrahepatic Cholangiocarcinoma
- Digestive System
The OPTIMIZE Trial
- Ages18 years - 80 years
- GenderBoth
- Stomach and Esophagus, Prostate Cancer, Bladder Cancer
Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung